Needham & Company Starts Albireo Pharma (ALBO) at Buy

July 18, 2017 6:56 AM EDT Send to a Friend
Needham & Company initiates coverage on Albireo Pharma (NASDAQ: ALBO) with a Buy rating and a price target of $35.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login